Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MGCD0103: Preliminary Phase I/II data

In the dose-escalation, Phase I portion of a U.S. Phase I/II trial, MGCD0103 plus Gemzar gemcitabine produced 1

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE